Business Wire

Business Figures for the First Half of 2019: Sartorius Continues Double-digit Growth


Sartorius, a leading international partner of biopharmaceutical research and the industry, grew strongly in the first half of 2019, recording double-digit increases in sales revenue, order intake and earnings. Given these results and continued positive prospects for the Bioprocess Solutions Division for the second half, management has raised its full-year targets.

“We are very pleased on the whole with business progress in the first half, though both divisions showed different growth dynamics,” said Executive Board Chairman and CEO Dr. Joachim Kreuzburg. “While growth in the lab business slowed down due to the currently uncertain and softer economic environment, especially at the end of the second quarter, momentum for Bioprocess Solutions has remained unchanged at a very high level. In view of further development, we are very confident and expect full-year sales growth of 10% to 14% instead of our previously forecasted 7% to 11%.”

Consolidated sales revenue in constant currencies rose in the first six months of the year by 15.9% to 894.7 million euros (reported: +18.0%); order intake increased 18.7% to 974.3 million euros (reported: +20.7%).

Underlying EBITDA rose overproportionately relative to sales by 25.4% to 237.6 million euros (H1 2018: 189.5 million euros); the respective margin reached 26.6% after 25.0% in the year-earlier period. About one percentage point of this increase was due, as expected, to the IFRS 16 Standard to be applied for the first time in 2019. Relevant net profit for the Group was up year over year by 27.3%, from 79.8 million euros to 101.5 million euros, which equates to earnings per ordinary share of 1.48 euros (H1 2018: 1.16) and to earnings per preference share of 1.49 euros (H1 2018: 1.17).

Business development in the regions

Sartorius grew by double digits in all regions: Reporting a sales gain of 19.9% to 224.5 million euros, the Asia | Pacific region showed the highest dynamics, followed by the Americas region, which increased its revenue by 18.9% to 308.2 million euros. The company also considerably expanded in EMEA (Europe, Middle East and Africa), which continued to account for the largest share of total Group sales, recording sales growth of 11.4% to 362.0 million euros.

Key financial indicators

The Sartorius Group continues to have a very sound balance sheet and financial base. Its ratio of net debt to underlying EBITDA edged down in comparison to December 31, 2018, from 2.4 to 2.3. The ratio of capital expenditures (CAPEX) to sales revenue, which is projected to further decrease in the second half upon completion of several large expansion projects, was 12.8% after the first six months of 2019 (H1 2018: 13.2%), as expected.2) Sartorius’ equity ratio decreased slightly from 38.5% at year-end 2018 to 37.6% as of June 30, 2019, predominantly due to the change in an accounting rule.1)

Business development of the divisions

The Bioprocess Solutions Division that offers a broad range of innovative technologies for the manufacture of biopharmaceuticals continued on the growth track with the high momentum seen at the beginning of the year. Based on strong demand across all product categories, particularly in project business in Asia, the division’s sales revenue surged 20.7% to 676.6 million euros (reported: +22.9%). Order intake for Bioprocess Solutions also rose substantially by 23.4% (reported: +25.5%) to 746.4 million euros.

The division’s underlying EBITDA increased by 28.8% to 198.3 million euros, and its earnings margin rose from 28.0% in the prior-year period to 29.3% due to economies of scale and as a result of the change in an accounting rule.1)

The Lab Products & Services Division that specializes in technologies and products for laboratories, primarily in the pharma sector and for life science research, saw more moderate sales growth than expected against the backdrop of a softer economic environment, especially at the end of the second quarter. The division’s sales rose 3.2% to 218.1 million euros (reported: +4.8%) against a strong prior-year revenue base. By contrast, order intake for Lab Products & Services increased relatively robustly by 5.4% (reported: +7.0%) to 228.0 million euros.

The division increased its underlying EBITDA by 10.9% to 39.4 million; the respective first-half margin rose year over year from 17.1% to 18.1%. Besides economies of scale, the change in an accounting rule1) also had a positive effect on this figure.

Guidance for the full year raised

Based on strong business performance in the first half and continued high demand, management has raised its financial guidance for the full year of 2019.

Group sales revenue for the full year is now projected to increase by about 10% to 14% in constant currencies compared to previous guidance of 7% to 11%. Regarding profitability, management continues to forecast that the company's underlying EBITDA margin will increase to slightly more than 27.0%, with the operating gain projected, as before, to amount to about half a percentage point and the remaining increase expected to result from changes in an accounting rule.1)

The ratio of capital expenditures (CAPEX) to sales revenue remains projected at around 12%, down from the year-earlier figure of 15.2%.2)

For the Bioprocess Solutions Division, management now expects that growth momentum will continue to exceed initial expectations and has raised its sales guidance from its previous forecast of about 8% to 12% to about 13% to 17%. Forecast for the division’s underlying EBITDA margin remains unchanged, which is expected to increase to slightly more than 29.5% relative to the prior-year figure of 28.6%. The operating gain of this increase is expected to amount to around half a percentage point.1)

For the Lab Products & Services Division, Sartorius now anticipates that due to the softer economic environment, the lower range of the division's sales forecast of about 5% to 9% will be reached. The division's underlying EBITDA margin is expected to be just below 20% (previous guidance: slightly above 20%), with the operating increase accounting for about half a percentage point.1)

All forecasts are based on constant currencies, as in the past years. A disorderly exit of the United Kingdom from the EU and an exacerbation of international trade disputes could impact supply chains in both divisions to a certain degree in spite of the measures already taken to counteract these developments. A reliable prognosis concerning possible effects cannot be made at the current time.

  1. IFRS 16 required to be applied as of 2019 regulates accounting of lease contracts. Ultimately, this has led to a somewhat extended balance sheet and thus to a slightly lower equity ratio. Further, this has resulted in reporting longer-term lease payments as depreciation and, accordingly, in a somewhat higher EBITDA, but does not entail any material changes concerning the Group’s relevant net profit or earnings per share.
  2. As of 2019, CAPEX is based on cash flow instead of balance sheet computation; CAPEX ratio restated: 13.1% for H1 2018; 14.9% for FY 2018

Alternative performance indicators:

  • Underlying EBITDA: Earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
  • Order intake: All customer orders contractually concluded during the respective reporting period.
  • Relevant net profit: Profit for the period after non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.

This press release contains statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events.

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

Conference call

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, and Rainer Lehmann, CFO, will discuss the company's business results with analysts and investors on Friday, July 19, 2019, at 3:30 p.m. Central European Summer Time (CEST) in a teleconference.

You may register by clicking on the following link:

Alternatively, you can dial into the teleconference, without registering in advance, at:
+49 (0) 69 566 03 7000

The presentation will be available on Friday, July 19, 2019, starting at 3:15 p.m. CEST, for viewing on our website at:

Current image files

Financial calendar

October 22, 2019

Publication of nine-month figures (January to September 2019)

Key Performance Indicators for the First Half of 2019

Sartorius Group

Bioprocess Solutions

Lab Products & Services

In millions of € (unless otherwise specified)



in % Reported

in % cc1)



in % Reported

in % cc1)



in % Reported

in % cc1)

Sales Revenue and Order Intake

Sales revenue













- EMEA2)













- Americas2)













- Asia | Pacific2)













Order intake



























EBITDA margin3) in %













Net profit for the period4)













Financial Data per Share

Earnings per
ordinary share4) in €













Earnings per preference share4) in €














  1. In constant currencies; abbreviated as "cc"
  2. Acc. to the customer’s location
  3. Underlying EBITDA: Earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
  4. Relevant net profit: Profit for the period after non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

A profile of Sartorius

The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, the company earned sales revenue of some 1.57 billion euros. Currently, around 8,700 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact information

Petra Kirchhoff | Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686 |

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newmont Publishes 2019 Sustainability Report1.6.2020 15:00:00 CESTPress release

Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine, a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance. “Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.” Newmont’s 2019 sustainability highlights include: Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed Further strengthening management of tailings, whilst enhancing transparency through a

New Western Union research provides insight into the future of international education1.6.2020 15:00:00 CESTPress release

The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today shares a new report on “The Future of International Education,” in partnership with The Future Laboratory. The white paper highlights five new student profiles that will evolve from the shifting attitudes and behaviors of today’s youth. From Hybrid Thinkers to Greener Graduates, this new report predicts how academic institutions should adapt to meet these expectations. This press release features multimedia. View the full release here: Meet the students of the future: new student profiles uncovered in “The Future of International Education” (Graphic: Business Wire) The findings come as universities and colleges worldwide are evolving to navigate COVID-19, from moving online, to delaying term dates. Institutions can use the report to ensure the new policies they introduce align with the needs and priorities of interna

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure1.6.2020 13:00:00 CESTPress release

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. This press release features multimedia. View the full release here: Impella RP is now FDA indicated for COVID-19 related complications, including pulmonary embolism. (Photo: Business Wire) Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure. Five years of pre- and post-market clinical studies support Impella RP’s safety and efficacy. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is

Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation1.6.2020 13:00:00 CESTPress release

Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation. “We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholest

Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast1.6.2020 13:00:00 CESTPress release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Peak, one of the most globally successful mobile gaming companies, for $1.8 billion. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga’s live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga’s new game pipeline with additional projects in early development. This press release features multimedia. View the full release here: Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast (Graphic: Business Wire) Founded in 2010 by Sidar Sahin, Peak has developed the

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin